TNF Inhibitors Found Not to Be Linked to Poor Pregnancy Outcomes
This data presented at ACR 2023 may provide relief to pregnant mothers as many stop taking them out of fear of harm to the fetus.
Stay updated with breaking news from Anna Molto. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This data presented at ACR 2023 may provide relief to pregnant mothers as many stop taking them out of fear of harm to the fetus.
According to new research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477).
EULAR has launched RheumaFacts, a novel resource for local and national data regarding rheumatic and musculoskeletal diseases in Europe, according to a presenter at the EULAR 2023 Congress.